PROKEarnings•globenewswire•
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Sentiment:Negative (15)
Summary
WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the second quarter ended June 30, 2025, and provided regulatory and clinical updates.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire